Compare Caesars Entertainment Inc (CZR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CZR | XBI | |
|---|---|---|
Market Cap | $6.02B | $10.11B |
Volume | 6,412,151 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $30.41 | $169.55 |
52-Week Low | $18.14 | $104.99 |
Typical Hold Time | 31 Days | 38 Days |
Enterprise Value | $29.91B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.50, up slightly by 0.03% today, with a bearish technical signal and neutral oscillators. The company reported a net loss of $502 million in 2025, missing earnings estimates for three consecutive quarters, while revenue remains stable near $11.5 billion. A pending merger with Fertitta Entertainment at $31.00 per share is under regulatory review, with several law firms investigating the deal's fairness.
CZR faces headwinds from persistent losses and high debt, but the merger offer provides a near-term price floor. Upside depends on operational turnaround and deal approval, while risks include earnings volatility and regulatory hurdles. Analyst consensus is mixed, with a hold-heavy rating and a $30.75 price target slightly above current levels.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
